United Therapeutics Corporation to Present at the TD Cowen 46th Annual Health Care Conference

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that Michael Benkowitz, President and Chief Operating Officer, will provide a company overview and update on Monday, March 2, 2026, from 2:30 to 3:00 p.m. EST, at the TD Cowen 46th Annual Health Care Conference in Boston. The presentation can be accessed via a live webcast on the United Therapeutics website at https://ir.unither.com/events-and-presentations. An arch.

Business Wire • Feb 23, 2026

USNA or UTHR: Which Is the Better Value Stock Right Now?

Investors interested in Medical - Drugs stocks are likely familiar with USANA Health Sciences (USNA) and United Therapeutics (UTHR). But which of these two stocks is more attractive to value investors?

Zacks Investment Research • Feb 23, 2026

Unveiling United Therapeutics (UTHR) Q4 Outlook: Wall Street Estimates for Key Metrics

Get a deeper insight into the potential performance of United Therapeutics (UTHR) for the quarter ended December 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.

Zacks Investment Research • Feb 20, 2026

United Therapeutics Corporation to Report Fourth Quarter and Full Year 2025 Financial Results Before the Market Opens on Wednesday, February 25, 2026

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its fourth quarter and full year 2025 financial results before the market opens on Wednesday, February 25, 2026. A press release detailing the quarterly results will be issued that day at approximately 6:30 a.m. Eastern Time. United Therapeutics will host a public webcast Wednesday, February 25, 2026, at 9:00 a.m. Eastern Time. The webcast will b.

Business Wire • Feb 11, 2026

United Therapeutics Announces Positive Results from Phase 1 Study of miroliverELAP® in Patients with Acute Liver Failure

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) today announced positive results from its phase 1 study of miroliverELAP®, an external liver assist product, in patients with acute forms of liver failure, acute-on-chronic liver failure, and severe acute alcoholic hepatitis, collectively called acute liver failure (ALF).2 Developed by Miromatrix Medical Inc., a wholly owned subsidiary of United Therapeutics, miroliverELAP consists.

Business Wire • Jan 26, 2026

United Therapeutics Corporation Announces Appointment of Kevin J. Tracey to its Board of Directors

SILVER SPRING, Md. & DURHAM, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the company's Board of Directors appointed Kevin J. Tracey, M.D., to its Board on January 21, 2026. Dr. Tracey is President, CEO, and the Karches Family Distinguished Chair in Medical Research at The Feinstein Institutes for Medical Research. He is a Professor of Molecular Medicine and Neurosurgery at the Donald and Barbara Zucker School of Medic.

Business Wire • Jan 22, 2026

Why United Therapeutics (UTHR) is a Top Growth Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Investment Research • Jan 16, 2026

Here's Why United Therapeutics (UTHR) is a Strong Value Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Investment Research • Jan 15, 2026

United Therapeutics Corporation (UTHR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

United Therapeutics Corporation (UTHR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Seeking Alpha • Jan 13, 2026

6 stocks and ETFs that these unsung market heroes see outperforming in 2026

Top stock-market newsletter editors share gems from their ‘buy' list.

Market Watch • Jan 12, 2026